Pharma Exclusives Pressreleases
BioMed X Advances Women’s Health Innovation at Inaugural XFem Labs Pitch & Connect Event
Tuesday, February 17, 2026BioMed X a leading innovation hub for pharma headquartered in Heidelberg hosted the first XFem Labs Pitch Connect event on February th in Heidelberg marking the official launch of XFem Labs its new Womens Health RD Accelerator
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
Wednesday, January 21, 2026Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
Friday, January 09, 2026Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announces an agreement with DCAI an AI infrastructure company which operates Gefion Denmarks supercomputer to strengthen and accelerate drug discovery
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
Tuesday, December 23, 2025Novo Nordisk today announced that the US Food and Drug Administration FDA has approved the Wegovy pill oncedaily oral semaglutide mg to reduce excess body weight and maintain weight reduction
Ipsen, Université de Montréal and IRICoR expand long-term partnership to accelerate early-stage oncology innovations
Monday, December 22, 2025Ipsen Universit de Montral and IRICoR of the Institute for Research in Immunology and Cancer IRIC at the Universit de Montral announced today a new research collaboration and option agreement
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Saturday, December 20, 2025Hansa Biopharma AB today announced the submission of a Biologics License Application BLA to the US Food and Drug Administration FDA for imlifidase The Company is requesting priority review of the BLA
Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
Wednesday, December 17, 2025Hansa Biopharma AB Hansa Nasdaq Stockholm HNSA today announced that GOODIDES a global pivotal Phase trial in antiglomerular basement membrane antiGBM disease did not meet its primary endpoint
Novo Nordisk has completed its acquisition of Akero Therapeutics
Wednesday, December 10, 2025Novo Nordisk and Akero Therapeutics Inc today announced that Novo Nordisks acquisition of Akero announced on October has been completed
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
Tuesday, December 09, 2025Roche announced today that the European Commission has approved GazyvaGazyvaro obinutuzumab in combination with mycophenolate mofetil MMF for the treatment of adult patients
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Tuesday, December 09, 2025ProBioGen and Spica Therapeutics Spica a pioneering biotechnology company advancing pathogenic macrophage subsettargeted immunotherapies today announced a new collaboration Under the agreement ProBioGen
